NanoString Technologies Competitors

Repligen (NASDAQ:RGEN) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Insider & Institutional Ownership

84.3% of Repligen shares are held by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are held by institutional investors. 1.7% of Repligen shares are held by company insiders. Comparatively, 4.2% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Repligen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Repligen and NanoString Technologies, as provided by MarketBeat.com.

Repligen currently has a consensus price target of $204.75, indicating a potential downside of 7.15%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than NanoString Technologies.

Profitability

This table compares Repligen and NanoString Technologies' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Repligen and NanoString Technologies' revenue, earnings per share (EPS) and valuation.

Repligen has higher revenue and earnings than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Summary

Repligen beats NanoString Technologies on 11 of the 14 factors compared between the two stocks.

QIAGEN (NYSE:QGEN) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Insider & Institutional Ownership

43.6% of QIAGEN shares are held by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are held by institutional investors. 9.0% of QIAGEN shares are held by company insiders. Comparatively, 4.2% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

QIAGEN has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for QIAGEN and NanoString Technologies, as provided by MarketBeat.com.

QIAGEN currently has a consensus price target of $56.3689, indicating a potential upside of 12.18%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given QIAGEN's higher possible upside, analysts clearly believe QIAGEN is more favorable than NanoString Technologies.

Profitability

This table compares QIAGEN and NanoString Technologies' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares QIAGEN and NanoString Technologies' revenue, earnings per share (EPS) and valuation.

NanoString Technologies has lower revenue, but higher earnings than QIAGEN. NanoString Technologies is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Summary

QIAGEN beats NanoString Technologies on 9 of the 14 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Insider & Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 4.2% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Neurocrine Biosciences has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Neurocrine Biosciences and NanoString Technologies' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Neurocrine Biosciences and NanoString Technologies' revenue, earnings per share (EPS) and valuation.

Neurocrine Biosciences has higher revenue and earnings than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Neurocrine Biosciences and NanoString Technologies, as provided by MarketBeat.com.

Neurocrine Biosciences currently has a consensus price target of $129.2222, indicating a potential upside of 18.40%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than NanoString Technologies.

Summary

Neurocrine Biosciences beats NanoString Technologies on 10 of the 14 factors compared between the two stocks.

CRISPR Therapeutics (NASDAQ:CRSP) and NanoString Technologies (NASDAQ:NSTG) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

66.4% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 17.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

CRISPR Therapeutics has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares CRISPR Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares CRISPR Therapeutics and NanoString Technologies' revenue, earnings per share and valuation.

CRISPR Therapeutics has higher revenue and earnings than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for CRISPR Therapeutics and NanoString Technologies, as reported by MarketBeat.

CRISPR Therapeutics currently has a consensus price target of $150.20, indicating a potential upside of 13.90%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given CRISPR Therapeutics' higher possible upside, equities analysts plainly believe CRISPR Therapeutics is more favorable than NanoString Technologies.

Summary

CRISPR Therapeutics beats NanoString Technologies on 11 of the 14 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and NanoString Technologies (NASDAQ:NSTG) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

68.2% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 19.3% of Denali Therapeutics shares are owned by company insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Denali Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Denali Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Denali Therapeutics and NanoString Technologies' revenue, earnings per share and valuation.

NanoString Technologies has higher revenue and earnings than Denali Therapeutics. NanoString Technologies is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Denali Therapeutics and NanoString Technologies, as reported by MarketBeat.

Denali Therapeutics currently has a consensus price target of $65.1111, indicating a potential downside of 1.32%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Denali Therapeutics is more favorable than NanoString Technologies.

Summary

Denali Therapeutics beats NanoString Technologies on 8 of the 14 factors compared between the two stocks.

Acceleron Pharma (NASDAQ:XLRN) and NanoString Technologies (NASDAQ:NSTG) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

79.8% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 2.5% of Acceleron Pharma shares are owned by company insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Acceleron Pharma has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Acceleron Pharma and NanoString Technologies' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Acceleron Pharma and NanoString Technologies' revenue, earnings per share and valuation.

NanoString Technologies has higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Acceleron Pharma and NanoString Technologies, as reported by MarketBeat.

Acceleron Pharma currently has a consensus price target of $139.6923, indicating a potential downside of 2.16%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Acceleron Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Acceleron Pharma is more favorable than NanoString Technologies.

Summary

NanoString Technologies beats Acceleron Pharma on 9 of the 15 factors compared between the two stocks.